Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
It is very uncertain whether the intervention changes all‐cause mortality at 31 to 100 days (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Number of participants with any bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in number of participants with any bleeding (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants with clinically significant bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in number of participants with clinically significant bleeding (0 to 3… (low certainty).
1 finding from 1 review
Intervention not reported
Serious infections (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in serious infections (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
Length of hospital admission (days) (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Hospital readmission (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The intervention showed no clear difference in hospital readmission (0 to 3 months) (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
Intervention not reported
Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP leads to lower mortality compared with chemotherapy including ABVD (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP probably leads to lower progression, relapse or death compared with chemotherapy including ABVD (moderate certainty).
1 finding from 1 review
Adverse event: treatment‐related mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: treatment‐related mortality compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: secondary malignancies compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies: AML or MDS · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP may leads to higher adverse event: secondary malignancies: AML or MDS compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: infertility (secondary amenorrhoea) · Patients with early unfavourable or advanced stage HL
It is very uncertain whether escalated BEACOPP changes adverse event: infertility (secondary amenorrhoea) compared with chemotherapy including ABVD (very low certainty).
1 finding from 1 review